Last reviewed · How we verify
Gleevec and Arsenic Trioxide
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor Used for Chronic myeloid leukemia, Acute promyelocytic leukemia.
At a glance
| Generic name | Gleevec and Arsenic Trioxide |
|---|---|
| Sponsor | New Mexico Cancer Research Alliance |
| Drug class | Tyrosine kinase inhibitor |
| Target | BCR-ABL, c-KIT, PDGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gleevec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR proteins. Arsenic trioxide is a differentiating agent that induces apoptosis in leukemia cells.
Approved indications
- Chronic myeloid leukemia
- Acute promyelocytic leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
Key clinical trials
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) (PHASE1)
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
- Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia (PHASE1, PHASE2)
- A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |